CL2021001635A1 - Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a - Google Patents
Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3aInfo
- Publication number
- CL2021001635A1 CL2021001635A1 CL2021001635A CL2021001635A CL2021001635A1 CL 2021001635 A1 CL2021001635 A1 CL 2021001635A1 CL 2021001635 A CL2021001635 A CL 2021001635A CL 2021001635 A CL2021001635 A CL 2021001635A CL 2021001635 A1 CL2021001635 A1 CL 2021001635A1
- Authority
- CL
- Chile
- Prior art keywords
- docetaxel
- cyp3a inhibitor
- combination therapy
- solid tumors
- treatments
- Prior art date
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 7
- 229960003668 docetaxel Drugs 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215488 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001635A1 true CL2021001635A1 (es) | 2022-04-22 |
Family
ID=64901398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001635A CL2021001635A1 (es) | 2018-12-21 | 2021-06-18 | Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220071944A1 (enExample) |
| EP (1) | EP3897611A1 (enExample) |
| JP (3) | JP2022514960A (enExample) |
| KR (1) | KR20220004011A (enExample) |
| CN (1) | CN113473982A (enExample) |
| AU (2) | AU2019410062A1 (enExample) |
| BR (1) | BR112021012266A2 (enExample) |
| CA (1) | CA3124319C (enExample) |
| CL (1) | CL2021001635A1 (enExample) |
| IL (1) | IL284225A (enExample) |
| MX (1) | MX2021007480A (enExample) |
| PE (1) | PE20220129A1 (enExample) |
| WO (1) | WO2020127607A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021012255A2 (pt) * | 2018-12-21 | 2021-09-28 | Modra Pharmaceuticals B.V. | Método para o tratamento de um câncer em um paciente, método para reduzir efeitos colaterais do tratamento de um câncer em um paciente, combinação de um inibidor de cyp3a e docetaxel para uso em um tratamento médico de um câncer, docetaxel para uso em uma terapia de combinação no tratamento de câncer, inibidor de cyp3a para uso em uma terapia de combinação no tratamento de câncer, uso e kit que compreende uma composição farmacêutica para administração oral que compreende docetaxel e uma composição farmacêutica que compreende um inibidor de cyp3a |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
| CN116270617B (zh) * | 2023-03-29 | 2024-01-26 | 济宁医学院附属医院 | Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101544498B1 (ko) * | 2007-08-24 | 2015-08-17 | 스티칭 허트 네덜란드 칸커 인스티튜트 | 종양성 질환의 치료를 위한 조성물 |
| GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| EP2328555A2 (en) | 2008-08-22 | 2011-06-08 | Slotervaart Participaties BV | Compositions for the treatment of neoplastic diseases |
| BR112021012255A2 (pt) * | 2018-12-21 | 2021-09-28 | Modra Pharmaceuticals B.V. | Método para o tratamento de um câncer em um paciente, método para reduzir efeitos colaterais do tratamento de um câncer em um paciente, combinação de um inibidor de cyp3a e docetaxel para uso em um tratamento médico de um câncer, docetaxel para uso em uma terapia de combinação no tratamento de câncer, inibidor de cyp3a para uso em uma terapia de combinação no tratamento de câncer, uso e kit que compreende uma composição farmacêutica para administração oral que compreende docetaxel e uma composição farmacêutica que compreende um inibidor de cyp3a |
-
2019
- 2019-12-18 CN CN201980090621.4A patent/CN113473982A/zh active Pending
- 2019-12-18 CA CA3124319A patent/CA3124319C/en active Active
- 2019-12-18 EP EP19828725.2A patent/EP3897611A1/en active Pending
- 2019-12-18 WO PCT/EP2019/086125 patent/WO2020127607A1/en not_active Ceased
- 2019-12-18 AU AU2019410062A patent/AU2019410062A1/en not_active Abandoned
- 2019-12-18 JP JP2021536396A patent/JP2022514960A/ja active Pending
- 2019-12-18 PE PE2021001053A patent/PE20220129A1/es unknown
- 2019-12-18 US US17/416,946 patent/US20220071944A1/en active Pending
- 2019-12-18 BR BR112021012266-4A patent/BR112021012266A2/pt not_active Application Discontinuation
- 2019-12-18 KR KR1020217022969A patent/KR20220004011A/ko not_active Ceased
- 2019-12-18 MX MX2021007480A patent/MX2021007480A/es unknown
-
2021
- 2021-06-18 CL CL2021001635A patent/CL2021001635A1/es unknown
- 2021-06-20 IL IL284225A patent/IL284225A/en unknown
-
2023
- 2023-05-01 JP JP2023075514A patent/JP2023102786A/ja active Pending
- 2023-07-14 AU AU2023204693A patent/AU2023204693A1/en not_active Abandoned
-
2025
- 2025-03-24 JP JP2025049063A patent/JP2025094186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020127607A1 (en) | 2020-06-25 |
| US20220071944A1 (en) | 2022-03-10 |
| EP3897611A1 (en) | 2021-10-27 |
| AU2023204693A1 (en) | 2023-08-10 |
| MX2021007480A (es) | 2021-10-13 |
| BR112021012266A2 (pt) | 2021-08-31 |
| JP2023102786A (ja) | 2023-07-25 |
| CN113473982A (zh) | 2021-10-01 |
| CA3124319C (en) | 2023-07-04 |
| CA3124319A1 (en) | 2020-06-25 |
| JP2025094186A (ja) | 2025-06-24 |
| AU2019410062A1 (en) | 2021-08-12 |
| PE20220129A1 (es) | 2022-01-27 |
| IL284225A (en) | 2021-08-31 |
| KR20220004011A (ko) | 2022-01-11 |
| JP2022514960A (ja) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| NI201900062A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| CL2021001635A1 (es) | Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a | |
| MX2020011727A (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de los mismos. | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| NI201800039A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| NI201800040A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| MX2019003134A (es) | Terapia de combinacion. | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| CL2021001638A1 (es) | Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| MX2018000872A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| CL2018003707A1 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo. | |
| MX2021011610A (es) | Combinaciones de iadademstat para terapia contra el cancer. | |
| MX394670B (es) | Agentes anticancerigenos y preparacion de los mismos. |